D.E. Shaw & Co
PMVP icon

D.E. Shaw & Co’s PMV Pharmaceuticals PMVP Stock Holding History

D.E. Shaw & Co’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-55,718
Closed -$78K – 4914
2025
Q3 		$78K Sell
55,718
-591,911
-91% -$819K ﹤0.01% 4377
2025
Q2 		$686K Sell
647,629
-302,097
-32% -$296K ﹤0.01% 3481
2025
Q1 		$1.04M Sell
949,726
-74,562
-7% -$101K ﹤0.01% 3065
2024
Q4 		$1.55M Sell
1,024,288
-16,189
-2% -$25.6K ﹤0.01% 2917
2024
Q3 		$1.55M Buy
1,040,477
+20,849
+2% +$32.2K ﹤0.01% 2912
2024
Q2 		$1.65M Buy
1,019,628
+298,993
+41% +$539K ﹤0.01% 2830
2024
Q1 		$1.23M Buy
720,635
+472,130
+190% +$882K ﹤0.01% 2957
2023
Q4 		$770K Buy
248,505
+219,707
+763% +$581K ﹤0.01% 3302
2023
Q3 		$177K Sell
28,798
-32,473
-53% -$223K ﹤0.01% 3784
2023
Q2 		$384K Buy
61,271
+6,414
+12% +$33.6K ﹤0.01% 3520
2023
Q1 		$262K Buy
54,857
+38,890
+244% +$274K ﹤0.01% 3803
2022
Q4 		$139K Buy
+15,967
New +$170K ﹤0.01% 4328
2021
Q1 		– Sell
-28,736
Closed -$1.77M – 4401
2020
Q4 		$1.77M Buy
+28,736
New +$1.13M ﹤0.01% 2635

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's PMVP Position: Q4 2025 in Review

D.E. Shaw & Co sold out of PMV Pharmaceuticals (PMVP) in Q4 2025, closing a stake of 55,718 shares — an estimated $78K sold.

D.E. Shaw & Co first reported a position in PMVP in Q4 2020 and held it in 13 quarters. The position peaked at $1.77M in Q4 2020. 63 funds tracked by Wall St. Rank hold PMVP as of Q4 2025.

  • D.E. Shaw & Co reported no remaining PMV Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 55,718 PMV Pharmaceuticals shares in Q4 2025, an estimated $78K.
  • D.E. Shaw & Co first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • D.E. Shaw & Co's PMV Pharmaceuticals position peaked at $1.77M in Q4 2020.
  • 63 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.